Roivant Sciences
Biotech Investor · 3 portfolio companies
Portfolio
3
Combined Value
$5.7B
Focus Areas
4
Top Stage
Phase 3
Portfolio Companies
| Company | Valuation |
|---|---|
| Immunovant | $5.7B |
| Pulmovant | — |
| Priovant Therapeutics | — |
Biotech Investor · 3 portfolio companies
| Company | Valuation |
|---|---|
| Immunovant | $5.7B |
| Pulmovant | — |
| Priovant Therapeutics | — |